Printer Friendly

ROBERTS PHARMACEUTICAL COMPLETES ACQUISITION OF NATIONAL CLINICAL RESEARCH CENTERS, INC.

 ROBERTS PHARMACEUTICAL COMPLETES ACQUISITION
 OF NATIONAL CLINICAL RESEARCH CENTERS, INC.
 EATONTOWN, N.J., April 7 /PRNewswire/ -- Roberts Pharmaceutical Corporation (NASDAQ: RPCX) announced today the completion of the previously announced acquisition of National Clinical Research Centers, Inc. (NCRC) of Bethesda, Md. The total purchase price of the acquisition was $6,250,000, consisting of $2.0 million in cash and 154,475 shares of Roberts Pharmaceutical common stock. NCRC, founded in 1985, had 1991 sales of just over $6 million and has a staff of approximately 70 employees.
 As a result of the acquisition, Roberts VRG subsidiary will combine operations with NCRC in order to expand and accelerate the NCRC unique Trial Management Organization (TMO) concept for assisting pharmaceutical companies in obtaining more rapid approval for new drugs. The VRG/NCRC organization will conduct its clinical research operations through a 24 bed Phase I clinical pharmacology unit, 11 research-dedicated outpatient clinics; a cost effective in-house patient recruiting system; a custom designed multi-purpose computerized study tracking system; on-site study coordinators with qualified contract investigators; multi-level quality control and sophisticated data management.
 Roberts chairman and CEO, Robert A. Vukovich, commented that, "We believe that this expanded business activity in the most time-consuming segment of the drug development process will provide substantial benefits to the growing list of VRG/NCRC clients."
 Roberts Pharmaceutical Corporation is engaged in the business of acquiring, developing and marketing human pharmaceuticals in the United States and abroad. The company is developing late stage pharmaceuticals for the treatment of cancer, respiratory disease, endocrine disorders, pain management, cardiovascular and urologic conditions. Roberts currently markets a line of prescription and non- prescription pharmaceuticals in the United States and abroad.
 -0- 4/7/92
 /CONTACT: Anthony P. Maris of Roberts Pharmaceuticals, 908-389-1182/
 (RPCX) CO: Roberts Pharmaceutical Corporation ST: New Jersey IN: MTC SU: TNM


SM-OS -- NY037 -- 5868 04/07/92 13:10 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 7, 1992
Words:310
Previous Article:BULGARIAN PRESIDENT ZHELYU ZHELEV TO OPEN SOFIA INTELLIGENCE CONFERENCE
Next Article:GREAT WESTERN BANK, FANNIE MAE TO PROVIDE $6 BILLION IN MORTGAGE FINANCING FOR HOME BUYERS IN 20 STATES


Related Articles
ROBERTS PHARMACEUTICAL CORPORATION TO ACQUIRE NATIONAL CLINICAL RESEARCH CENTERS
DEFINITIVE ACQUISITION AGREEMENT SIGNED BETWEEN ROBERTS PHARMACEUTICALS AND NATIONAL CLINICAL RESEARCH CENTERS
IVAX COMPLETES ACQUISITION OF FLORI ROBERTS, INC.
ROBERTS PHARMACEUTICAL ACQUIRES COMHIST ANTI-ALLERGY PRESCRIPTION PHARMACEUTICAL PRODUCT LINE FROM PROCTER & GAMBLE PHARMACEUTICALS
ROBERTS PHARMACEUTICAL CORPORATION ACQUIRES ETHMOZINE, A CURRENTLY MARKETED CARDIOVASCULAR DRUG FROM DU PONT MERCK
ROBERTS PHARMACEUTICAL CORPORATION FILES NEW DRUG APPLICATION FOR AGRELIN WITH FDA
ROBERTS PHARMACEUTICAL COMPLETES ACQUISITION OF ETHMOZINE FROM DU PONT MERCK
ROBERTS PHARMACEUTICAL CORPORATION RECEIVES CANADIAN REGULATORY APPROVAL FOR AGRELIN(R) TREATMENT IND
ROBERTS PHARMACEUTICAL CORPORATION APPOINTS VICE PRESIDENT, DEVELOPMENTAL THERAPEUTICS
ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES UK/ROI ACQUISITION OF PRESCRIPTION PRODUCT MAXOLON FROM SMITHKLINE BEECHAM

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters